

The unique advantages of BD Barricor tubes are enabled through an innovative mechanical separation technology which allows the separation of cellular content throughout the centrifugation cycle” BD (2016).

BD report “BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Vacutainer® Barricor™ plasma blood collection tube (BD Barricor), the next generation blood collection and separation technology designed to improve sample quality, help clinicians receive test results faster, and ultimately improve patient care and clinical efficiency...

ReTweet if useful... BD receives FDA 510K clearance for BD Barrier blood collection tubes
[@ivteam #ivteam](http://ctt.ec/e5rzL+)

Click To Tweet

...The unique advantages of BD Barricor tubes are enabled through an innovative mechanical separation technology which allows the separation of cellular content throughout the centrifugation cycle. As a result, the BD Barricor tube reduces plasma cellular content while also eliminating gel artifacts that can lead to instrument downtime. A cleaner plasma sample improves analyte stability, thereby increasing the window to conduct testing when compared to leading blood separation tubes. Additionally, the mechanical separator is designed not to absorb hydrophobic drugs and can be used as for therapeutic drug testing. As BD Barricor tubes have the potential to reduce manual sample remediation and instrument maintenance, improved laboratory efficiency and lower laboratory costs are also expected.”

Full Press Release

Thank you to our partners for supporting IVTEAM